AMAG Pharmaceuticals, Inc. (AMAG) Receives Consensus Rating of “Hold” from Analysts

Shares of AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) have earned a consensus recommendation of “Hold” from the eighteen research firms that are presently covering the stock, MarketBeat reports. Two equities research analysts have rated the stock with a sell recommendation, twelve have assigned a hold recommendation and three have assigned a buy recommendation to the company. The average 12 month price objective among analysts that have covered the stock in the last year is $22.20.

Several analysts have recently issued reports on the company. ValuEngine upgraded AMAG Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Tuesday, July 25th. Zacks Investment Research cut AMAG Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, July 26th. Cantor Fitzgerald reiterated a “hold” rating on shares of AMAG Pharmaceuticals in a research note on Monday, July 24th. Morgan Stanley assumed coverage on AMAG Pharmaceuticals in a research note on Friday, September 8th. They issued an “overweight” rating and a $26.00 price objective on the stock. Finally, BidaskClub cut AMAG Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, August 10th.

COPYRIGHT VIOLATION NOTICE: This report was posted by Markets Daily and is the sole property of of Markets Daily. If you are viewing this report on another site, it was illegally stolen and republished in violation of U.S. & international copyright laws. The original version of this report can be read at https://www.themarketsdaily.com/2017/11/13/amag-pharmaceuticals-inc-amag-receives-consensus-rating-of-hold-from-analysts.html.

Shares of AMAG Pharmaceuticals (NASDAQ AMAG) traded down $0.15 during midday trading on Monday, hitting $14.05. The stock had a trading volume of 763,600 shares, compared to its average volume of 1,126,475. The company has a debt-to-equity ratio of 0.94, a quick ratio of 1.48 and a current ratio of 1.59. AMAG Pharmaceuticals has a twelve month low of $11.93 and a twelve month high of $36.83.

Several hedge funds have recently modified their holdings of AMAG. OppenheimerFunds Inc. grew its holdings in shares of AMAG Pharmaceuticals by 101.1% during the first quarter. OppenheimerFunds Inc. now owns 17,575 shares of the specialty pharmaceutical company’s stock worth $396,000 after purchasing an additional 8,836 shares during the last quarter. Teachers Advisors LLC grew its holdings in shares of AMAG Pharmaceuticals by 3.6% during the first quarter. Teachers Advisors LLC now owns 62,055 shares of the specialty pharmaceutical company’s stock worth $1,399,000 after purchasing an additional 2,164 shares during the last quarter. Legal & General Group Plc grew its holdings in shares of AMAG Pharmaceuticals by 1.3% during the first quarter. Legal & General Group Plc now owns 61,371 shares of the specialty pharmaceutical company’s stock worth $1,384,000 after purchasing an additional 770 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of AMAG Pharmaceuticals by 6.1% during the first quarter. Vanguard Group Inc. now owns 3,085,348 shares of the specialty pharmaceutical company’s stock worth $69,576,000 after purchasing an additional 176,832 shares during the last quarter. Finally, Dimensional Fund Advisors LP grew its holdings in shares of AMAG Pharmaceuticals by 152.4% during the first quarter. Dimensional Fund Advisors LP now owns 1,025,673 shares of the specialty pharmaceutical company’s stock worth $23,129,000 after purchasing an additional 619,370 shares during the last quarter.

AMAG Pharmaceuticals Company Profile

AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.

Analyst Recommendations for AMAG Pharmaceuticals (NASDAQ:AMAG)

Receive News & Ratings for AMAG Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply